You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 25, 2024

EYSUVIS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Eysuvis, and what generic alternatives are available?

Eysuvis is a drug marketed by Alcon Labs Inc and is included in one NDA. There are sixteen patents protecting this drug.

This drug has eighty-four patent family members in twelve countries.

The generic ingredient in EYSUVIS is loteprednol etabonate. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Eysuvis

A generic version of EYSUVIS was approved as loteprednol etabonate by SENTISS on April 17th, 2019.

  Sign Up

Summary for EYSUVIS
Drug patent expirations by year for EYSUVIS
Drug Prices for EYSUVIS

See drug prices for EYSUVIS

Recent Clinical Trials for EYSUVIS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Kala Pharmaceuticals, Inc.Phase 4
Price Vision GroupPhase 4

See all EYSUVIS clinical trials

Pharmacology for EYSUVIS
Anatomical Therapeutic Chemical (ATC) Classes for EYSUVIS

US Patents and Regulatory Information for EYSUVIS

EYSUVIS is protected by sixteen US patents.

Patents protecting EYSUVIS

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Labs Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alcon Labs Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alcon Labs Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Alcon Labs Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Alcon Labs Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Alcon Labs Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Alcon Labs Inc EYSUVIS loteprednol etabonate SUSPENSION/DROPS;OPHTHALMIC 210933-001 Oct 26, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for EYSUVIS

See the table below for patents covering EYSUVIS around the world.

Country Patent Number Title Estimated Expiration
Australia 2013256092 Pharmaceutical nanoparticles showing improved mucosal transport ⤷  Sign Up
Japan 7320219 ⤷  Sign Up
South Korea 102310775 ⤷  Sign Up
Hong Kong 1208382 顯示提高的粘膜轉移的藥物納米粒子 (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT) ⤷  Sign Up
Mexico 2016005710 COMPOSICIONES Y METODOS PARA APLICACIONES OFTALMICAS Y/U OTRAS APLICACIONES. (COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS.) ⤷  Sign Up
Chile 2019003433 Composición farmacéutica oftálmica que comprende nanopartículas mucopenetrantes, cuyo núcleo comprende un agente activo farmacéutico seleccionado entre un inhibidor de receptor tirosina quinasa (rtk), o un inhibidor de la angiogénesis, y está recubierto con un polímero modificador de superficie; y uso para tratar un trastorno del ojo (divisional de solicitud cl 2956-2014). ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2013166436 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.